



## Claim History

**I claim:**

**1. (Previously amended) An immunophilin, comprising a protein with the following properties:**

- (i) a protein of 8.4 kDa mass;**
- (ii) isolated from the soluble cytoplasm of lymphoid tissues;**
- (iii) the N-terminal first 23 amino acid sequence is:**

<b>Met Gln Ile Phe Val Lys Thr Leu Thr Gly</b>	<b>10</b>	<b>Seq. ID No. 1</b>
<b>Lys Thr Ile Thr Leu Glu Val Glu Pro Ser</b>	<b>20</b>	
<b>Asp Thr Ile</b>	<b>23</b>	

**and,**

**(iv) capable of specifically binding FK-506, rapamycin, or pharmacologically active metabolites thereof or pharmacologically active derivatives of rapamycin, but not cyclosporins.**

**2. (Original) An immunophilin according to claim1, wherein said protein has a retention time on HPLC the same as authentic ubiquitin.**

**3.(Original) An immunophilin according to claim 1, wherein said protein migrates on SDS-PAGE electrophoresis plates identically to authentic ubiquitin.**

**4. (Previously amended) An immunophilin according to claim 1, wherein said protein exhibits a binding constant (Kd) of about 0.8 nM for FK-506 and 0.08 nM for rapamycin.**

**5. (Original) An immunophilin according to claim 1, wherein said protein has a Hill plot value of about unity.**

**6. (Original) An immunophilin according to claim 1, wherein said protein, when complexed to FK-506, inhibits calcineurin phosphatase activity.**

**7. Canceled.**

**8. Canceled**

**9. (Canceled)**